Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2693 in NASH with Fibrosis (FORTUNA)
NCT05809934Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 22
01
Overview
A Phase 2 trial of AZD2693 in Nonalcoholic steatohepatitis (NASH), sponsored by AstraZeneca. Started Mar 2023; status: completed.
02
Drugs
AZD2693
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05809934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809934.